Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders Read More.
Find the latest analyst research for Organovo Holdings, Inc. Common Stock (ONVO) at Nasdaq.com.
Organovo Holdings Inc. ONVO 0.60 0.00 (0.57%). NASDAQ Updated Jun 17, 2020 9:58 PM.Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Rewards Earnings have grown 8.6% per year over the past 5 years.PESTEL analysis provides great detail about operating challenges Organovo Holdings, Inc. will face in prevalent macro environment other than competitive forces. For example an Industry may be highly profitable with a strong growth trajectory but it won't be any good for Organovo Holdings, Inc. if it is situated in unstable political environment.
Organovo is an early-stage medical laboratory and research company which designs and develops functional, three dimensional human tissue (also known as 3D bioprinting technology) for medical research and therapeutic applications. Organovo was established in 2007 and is headquartered in San Diego, California.The company uses its internally developed NovoGen MMX Bioprinter for 3D bioprinting.Read More
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D.Read More
Stock analysis for Organovo Holdings Inc (ONVO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Read More
Organovo Holdings, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Organovo Holdings, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Organovo Holdings, Inc. or its management.Read More
Organovo Holdings Inc. ONVO Morningstar Rating Rating as of Jun 4, 2020. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation.Read More
Organovo's top competitors are Aspect, Anika and InSphero. See Organovo's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform.Read More
Simply Wall St April 6, 2018 Measuring Organovo Holdings Inc’s ( NASDAQ:ONVO ) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, which is a powerful signal for future performance.Read More
Organovo Holdings, Inc. (NASDAQ:ONVO) is a development stage company with the aim to produce functional human tissues to be used in drug discovery and development.These tissues will also be.Read More
For the transition period from to. Commission File Number 001-35996 Organovo Holdings, Inc. (Exact name of registrant as specified in its charter).Read More